Viewing Study NCT05927857


Ignite Creation Date: 2025-12-24 @ 7:08 PM
Ignite Modification Date: 2025-12-27 @ 11:14 PM
Study NCT ID: NCT05927857
Status: RECRUITING
Last Update Posted: 2025-08-22
First Post: 2023-06-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Sponsor: National Health Research Institutes, Taiwan
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module